Phase 1 safety trial of FPA144 in patients with gastric cancer in Japan
Phase of Trial: Phase I
Latest Information Update: 08 Aug 2017
Price : $35 *
At a glance
- Drugs Bemarituzumab (Primary)
- Indications Gastric cancer
- Focus Adverse reactions
- 08 Aug 2017 According to a Five Prime Therapeutics media release, the completion of this trial is intended to enable the inclusion of Japanese patients in the planned global Phase 3 clinical trial.
- 17 Jul 2017 According to a Five Prime Therapeutics media release, dosing has been initiated in this trial.
- 17 Jul 2017 Status changed from planning to recruiting, according to a Five Prime Therapeutics media release.